Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

Arms (1)

1. type

   EXPERIMENTAL

   label

   Orelabrutinib Combined with chemotherapy followed by monotherapy in ND MCD subtype DLBCL

   description

   For MCD subtype DLBCL (including IP-LBCLs) that have undergone two cycles of induction therapy, combine orelabrutinib treatment starting from the third cycle. For patients with poor prognostic factors (meeting one of the following: Ann Arbor stage III/IV; IPI score 3-5; aaIPI score 2-3; high-intermediate or high-risk group per MSKCC and/or IELSG criteria), continue with two additional cycles of orelabrutinib-combined induction therapy, followed by orelabrutinib monotherapy maintenance for 2 years or until disease progression or intolerable toxicity. For patients without poor prognostic factors, administer orelabrutinib monotherapy maintenance for 1 year or until disease progression or intolerable toxicity.

   interventionNames

   1. Drug: R-CHOP+Orelabrutinib
   2. Drug: POLA-R-CHP+orelabrutinib
   3. Drug: R-miniCHOP +orelabrutinib
   4. Drug: Zuberitamab-CHOP+orelabrutinib
   5. Drug: POLA-Hi-CHP+orelabrutinib
   6. Drug: Hi-miniCHOP +orelabrutinib
   7. Drug: RMTO
   8. Drug: HiMTO
   9. Drug: Pola-R-miniCHP+O
   10. Drug: Pola-Hi-miniCHP

Primary outcomes (1)

1. measure